RT Journal Article
SR Electronic
T1 PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 97S
OP 104S
DO 10.2967/jnumed.115.170167
VO 57
IS Supplement 3
A1 Harshad R. Kulkarni
A1 Aviral Singh
A1 Christiane Schuchardt
A1 Karin Niepsch
A1 Manal Sayeg
A1 Yevgeniy Leshch
A1 Hans-Juergen Wester
A1 Richard P. Baum
YR 2016
UL http://jnm.snmjournals.org/content/57/Supplement_3/97S.abstract
AB A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with 177Lu-PSMA ligands. 68Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring. Our comprehensive experience over the last 3 years using different radioligands indicates that PRLT is highly effective for the treatment of mCRPC, even in advanced cases, and potentially lends a significant benefit to overall and progression-free survival. Additionally, significant improvement in clinical symptoms and excellent palliation of pain can be achieved.